CVS Caremark ordered to pay $290M after Medicare fraud scheme exposed by former Aetna whistleblower
Werte in diesem Artikel
A federal judge has ordered CVS Health’s pharmacy benefit manager, Caremark, to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.Sarah Behnke, a former Aetna actuary, alleged Caremark defrauded Medicare Part D by causing false drug cost reports to be submitted in 2013 and 2014.Caremark was found liable in June and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay $95 million in damages, deferring final rulings on penalties.Goldberg, who was appointed by former President George W. Bush, tripled the damages on Tuesday, finding Caremark Rx, CaremarkPCS Health and CVS Caremark Part D Services should pay a total of $289.9 million in damages and penalties, according to court documents. Goldberg also imposed $4.87 million in civil penalties.ANTI-THEFT MEASURES AT CVS ARE 'WORSE FOR BUSINESS THAN ORGANIZED SHOPLIFTING,' COLUMNIST ARGUES"We are pleased that the Behnke ruling in June was in our favor as to certain issues for CVS Pharmacy and CVS Health Corporation’s liability, and disappointed the Court found against Caremark on other issues. We plan to appeal," CVS wrote in a statement to FOX Business.In 2014, Caremark was accused of manipulating how drug costs were reported, causing Aetna and SilverScript to submit false direct and indirect remuneration reports in 2013 and 2014, according to court records.The scheme, which was allegedly designed to hide profits, led to Medicare Part D being overbilled by $95 million.LOS ANGELES WILDFIRES: BIG BUSINESSES MAKE DONATIONS, OFFER SERVICES TO THOSE IMPACTED BY INFERNOSWhile Goldberg did not find "actual knowledge" of the fraud, he found reckless disregard and deliberate ignorance warranting the steep penalties, according to a memorandum.Caremark argued that the 513 false reports submitted did not justify penalties exceeding the $95 million overcharged, citing the excessive fines clause of the Eighth Amendment and the due process clause.However, Goldberg found a $95 million fraud loss was "certainly significant."Citing precedent from a State Farm insurance case in 2003, Goldberg noted due process was not violated because the ratio of penalties to actual damages was substantially lower than previous decisions, according to court documents.CVS OPENS SMALLER FORMAT STORES AS INDUSTRY SEES BIG SHIFTGoldberg also awarded post-judgment interest, which means interest began accruing on the total $289.9 million on Tuesday, and will continue to accrue until Caremark pays in full.The interest will compensate Behnke and the government until CVS pays fully, preventing the company from delaying action.It is unclear how much of the total award Behnke will receive.GET FOX BUSINESS ON THE GO BY CLICKING HEREAetna, Sarah Behnke and U.S. Attorney David Metcalf did not immediately respond to FOX Business' requests for comment.Weiter zum vollständigen Artikel bei FOX Business
Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Aetna
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aetna
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: FOX Business
Nachrichten zu CVS Health Corp
Analysen zu CVS Health Corp
Datum | Rating | Analyst | |
---|---|---|---|
05.06.2019 | CVS Health Buy | Standpoint Research | |
15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
18.12.2018 | CVS Health Overweight | Barclays Capital | |
26.10.2018 | CVS Health Peer Perform | Wolfe Research |
Datum | Rating | Analyst | |
---|---|---|---|
05.06.2019 | CVS Health Buy | Standpoint Research | |
12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
18.12.2018 | CVS Health Overweight | Barclays Capital | |
30.01.2018 | CVS Health Strong Buy | Needham & Company, LLC | |
02.01.2018 | CVS Health Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
26.10.2018 | CVS Health Peer Perform | Wolfe Research | |
28.06.2017 | CVS Health Hold | Needham & Company, LLC | |
02.02.2017 | CVS Health Neutral | Robert W. Baird & Co. Incorporated | |
22.06.2016 | CVS Health Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
25.07.2005 | Update Longs Drug Stores Corp.: Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen